AZN Jan 2025 75.000 call
| Previous Close | 4.9500 |
| Open | 4.9500 |
| Bid | 5.3500 |
| Ask | 5.5500 |
| Strike | 75.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 4.9500 - 4.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 326 |
ZacksIs it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
ZacksAstrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.
- Reuters
UPDATE 3-J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
Johnson & Johnson said its cancer drug combination increased the time patients with a type of non small-cell lung cancer live without the disease worsening compared to AstraZeneca's Tagrisso in a late-stage study. J&J said on Thursday it expects the combination to become a first-line treatment for non small-cell lung cancer (NSCLC) patients with a type of mutation in EGFR protein that causes rapid tumor cell growth. An interim analysis of data on overall survival for patients showed a trend "favoring" the combination therapy compared to AstraZeneca's blockbuster drug, J&J said, without revealing complete details about the extent of the therapy's benefits.
